FGFR3 and neoplasm: A pan-FGFR inhibitor, erdafitinib, displayed a meaningful tumor response rate in patients with urothelial carcinoma, indicating that it could be especially beneficial to those with FGFR3-activated tumors, suggesting a promising targetable axis of the double-high group [21,26].